Shu Li

机构：Johnson & Johnson (United States), Johnson & Johnson (Israel) · ORCID：0000-0003-3164-1348

发表论文 58 篇 · 总被引 12465 次 · h-index 32

代表论文

• Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1) (2008 · The Lancet · 被引 1875)
• Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2) (2008 · The Lancet · 被引 1365)
• Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial (2017 · Journal of the American Academy of Dermatology · 被引 898)
• Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis (2010 · New England Journal of Medicine · 被引 858)
• Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial (2013 · The Lancet · 被引 805)
• Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator–controlled VOYAGE 2 trial (2017 · Journal of the American Academy of Dermatology · 被引 767)